Prospects for Pharmacological Intervention in Alzheimer Disease
Open Access
- 1 April 2000
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 57 (4), 454-459
- https://doi.org/10.1001/archneur.57.4.454
Abstract
Alzheimer disease (AD) involves neuronal degeneration with impaired cholinergic transmission in the cerebral cortex and hippocampus in areas of the brain particularly associated with memory and higher intellectual functioning. Other neurotransmitter deficits also occur, but the mechanisms underlying the widespread impairment of synaptic functions remain uncertain. Research on the molecular basis of AD has elucidated a pathogenic pathway from which a range of rational pharmacological interventions has emerged. Although at least 3 cholinesterase inhibitors (tacrine hydrochloride, donepezil, and rivastigmine tartrate) are now available and provide patients with modest relief, the most promising strategy involves approaches to retarding, halting, or preventing the formation or accumulation of β-amyloid (Aβ) plaques. Estrogen is believed to have antioxidant or other anti-Aβ effects, as hormonal replacement therapy in women with menopause is associated with a reduced risk or delayed onset of AD. The association between nonsteroidal anti-inflammatory drugs and a reduced risk of AD has not yet been confirmed, but these agents may protect the brain from the reactive glial and microglial responses associated with Aβ deposition. Also, recent studies suggested that antioxidants, such as vitamin E taken alone or in combination with selegiline hydrochloride, can delay the progression of AD. Despite these encouraging results, no current therapy has been shown to halt or reverse the underlying disease process. The proof of the principle that anti-Aβ drugs will work in the transgenic models of AD is eagerly awaited with the expectation that they will eventually prove successful in humans.This publication has 11 references indexed in Scilit:
- Memantine in severe dementia: results of the9M-best study (benefit and efficacy in severly demented patients during treatment with memantine)International Journal of Geriatric Psychiatry, 1999
- Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administrationBritish Journal of Clinical Pharmacology, 1998
- Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in agingNeurology, 1998
- Estrogen reduces neuronal generation of Alzheimer β-amyloid peptidesNature Medicine, 1998
- Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre studyPublished by Springer Science and Business Media LLC ,1998
- A 12-Month, Randomized, Placebo-Controlled Trial of Propentofylline (HWA 285) in Patients with Dementia According to DSM III-RDementia and Geriatric Cognitive Disorders, 1997
- Effects of metrifonate on memory impairment and cholinergic dysfunction in ratsEuropean Journal of Pharmacology, 1997
- Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age‐related neurodegenerationNeurology, 1993
- Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine ReceptorsScience, 1992
- Characterisation of Dopamine and Serotonin Uptake Inhibitory Effects of Tetrahydroaminoacridine in Rat BrainBasic & Clinical Pharmacology & Toxicology, 1992